PRODUCT MONOGRAPH

PrHALAVEN®

(eribulin mesylate) injection

0.5 mg/mL

Antineoplastic Agent

Eisai Limited
2630 Skymark Avenue
Mississauga, Ontario
L4W 5A4

Date of Revision:
January 17, 2013

Submission Control No: 159599

HALAVEN® is a trademark owned by Eisai R&D Management Co., Ltd.
Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION .................................................................3
  SUMMARY PRODUCT INFORMATION ........................................................................3
  INDICATIONS AND CLINICAL USE ........................................................................3
  CONTRAINDICATIONS ..............................................................................................3
  WARNINGS AND PRECAUTIONS ............................................................................4
  ADVERSE REACTIONS .............................................................................................7
  DRUG INTERACTIONS .............................................................................................11
  DOSAGE AND ADMINISTRATION ........................................................................12
  OVERDOSAGE .........................................................................................................14
  ACTION AND CLINICAL PHARMACOLOGY .........................................................15
  STORAGE AND STABILITY ....................................................................................17
  SPECIAL HANDLING INSTRUCTIONS .....................................................................17
  DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................17

PART II: SCIENTIFIC INFORMATION ..............................................................................18
  PHARMACEUTICAL INFORMATION ........................................................................18
  CLINICAL TRIALS ..................................................................................................19
  DETAILED PHARMACOLOGY ................................................................................22
  TOXICOLOGY ..........................................................................................................23
  REFERENCES ...........................................................................................................26

PART III: CONSUMER INFORMATION .............................................................................27
PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Dosage Form / Strength</th>
<th>Clinically Relevant Non-medicinal Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intravenous</td>
<td>Solution for injection: 0.5 mg/mL</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>For a complete listing see Dosage Forms, Composition and Packaging section.</td>
</tr>
</tbody>
</table>

INDICATIONS AND CLINICAL USE

HALAVEN is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane administered in either the adjuvant or metastatic setting.

Geriatrics (> 65 years of age):
No dose adjustments are recommended based on the age of the patient (see WARNINGS AND PRECAUTIONS – Geriatrics (>65 years of age)).

Pediatrics (< 18 years of age):
The safety and effectiveness of HALAVEN in pediatric patients have not been established.

CONTRAINDICATIONS

HALAVEN is contraindicated in patients with a history of hypersensitivity to HALAVEN or halichondrin B or its chemical derivatives.
WARNINGS AND PRECAUTIONS

**Serious Warnings and Precautions**

- Neutropenia (see WARNINGS AND PRECAUTIONS, and DOSAGE AND ADMINISTRATION)
- QT/QTc interval prolongation (see WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests; DRUG INTERACTIONS; ACTION AND CLINICAL PHARMACOLOGY, Electrocardiography)
- HALAVEN has not been studied in patients with severe hepatic or renal impairment

HALAVEN should be administered under the supervision of a physician experienced in the use of anti-cancer agents.

**Carcinogenesis and Mutagenesis**

Carcinogenicity studies were not conducted with eribulin mesylate.

Eribulin mesylate was positive in mammalian genotoxicity studies (see TOXICOLOGY – Genotoxicity).

**Cardiovascular**

HALAVEN is associated with QT/QTc interval prolongation (see WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests; DRUG INTERACTIONS; ACTION AND CLINICAL PHARMACOLOGY, Electrocardiography). Many drugs that cause QT/QTc prolongation are suspected to increase the risk of torsade de pointes. If sustained, torsade de pointes can progress to ventricular fibrillation and sudden cardiac death.

Use of HALAVEN in patients with congenital long QT/QTc syndrome should be avoided. The concomitant use of HALAVEN with another QT/QTc-prolonging drug should be avoided to the extent possible (see DRUG INTERACTIONS).

The safety of HALAVEN has not been established in patients with significant cardiovascular impairment (history of congestive heart failure New York Heart Association > Grade 2, unstable angina or myocardial infarction within the previous 6 months, or serious cardiac arrhythmia).

**Hematologic**

Myelosuppression is dose dependent and primarily manifested as neutropenia. Febrile neutropenia occurred in 5% of patients receiving HALAVEN. Fatal outcome has been observed due to complications with neutropenia.
Patients should have Absolute Neutrophil Count (ANC) values ≥1,500 cells/mm³ and platelets >100,000/mm³ at the initiation of treatment with HALAVEN. Frequent monitoring of complete blood counts should be performed on all patients receiving HALAVEN. Patients should only be retreated with HALAVEN when ANC is ≥1,000 cells/mm³, platelets are ≥75,000/mm³, and any other toxicity of a previous cycle has recovered to Grade ≤2 (except anemia) (see DOSAGE AND ADMINISTRATION).

Patients experiencing febrile neutropenia, severe neutropenia, or thrombocytopenia may require a subsequent reduction of the dose of HALAVEN.

Patients with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 × the upper limit of normal (ULN) or bilirubin >1.5 × ULN experienced a higher incidence of Grade 4 neutropenia and febrile neutropenia. Reduction of the starting dose for patients with ALT or AST >3 x ULN or bilirubin >1.5 x ULN should be considered. These patients should be monitored closely for toxicity.

**Neurologic**

Grade 3 peripheral neuropathy occurred in 8% (40/503) of patients, and Grade 4 in 0.4% (2/503) of patients in a pivotal study. Peripheral neuropathy was the most common toxicity leading to discontinuation of HALAVEN (5% of patients; 24/503). Neuropathy lasting more than one year occurred in 5% (26/503) of patients. Twenty-two percent (109/503) of patients developed a new or worsening neuropathy that had not recovered by the end of their follow-up period (median follow-up duration = 269 days, range 25–662 days).

Monitor patients closely for signs of peripheral neuropathy. Dosage in patients experiencing peripheral neuropathy should be adjusted according to the recommendations in Table 4 (see DOSAGE AND ADMINISTRATION).

HALAVEN may aggravate existing neuropathy and should be used with caution in patients with pre-existing neuropathy.

**Special Populations**

**Pregnant Women:**
HALAVEN is a microtubule inhibitor, therefore, it is expected to cause fetal harm when administered to pregnant women. Embryo-fetal toxicity and teratogenicity occurred in pregnant rats that received eribulin mesylate at approximately half of the recommended human dose based on body surface area (see TOXICOLOGY section). There are no adequate and well-controlled studies with HALAVEN in pregnant women. Women should be advised not to become pregnant when taking HALAVEN. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
Nursing Women:
It is not known whether HALAVEN is excreted into human milk. Because many drugs are excreted into human milk and because of the potential for serious adverse reactions to HALAVEN in nursing infants, breast feeding must be avoided.

Pediatrics (< 18 years of age):
The safety and effectiveness of HALAVEN in pediatric patients have not been established.

Geriatrics (> 65 years of age):
Among the 827 patients who received the recommended dose of HALAVEN in the Phase 2/3 breast cancer studies, 121 patients (15%) were >65 -75 years of age and 17 patients (2%) were >75 years of age. The safety profile of HALAVEN in elderly patients (>65 years of age) was similar to that of patients ≤65 years of age. No dose adjustments are recommended based on the age of the patient.

Hepatic Impairment:
Patients with mild or moderate hepatic impairment should receive a reduced dose. The recommended dose for patients with mild hepatic impairment (Child-Pugh A) is 1.1 mg/m². The recommended dose for patients with moderate hepatic impairment (Child-Pugh B) is 0.7 mg/m². HALAVEN was not studied in patients with severe hepatic impairment (Child-Pugh C); therefore, the use of HALAVEN is not recommended in these patients (see DOSAGE AND ADMINISTRATION, and ACTION AND CLINICAL PHARMACOLOGY – Special Populations and Conditions).

Renal Impairment:
Mild (creatinine clearance, CrCl: 50-80 mL/min) or moderate renal impairment (CrCl: 30-50 mL/min) could cause decrease in clearance of eribulin. Up to 2-fold increase in exposure to eribulin may occur in patients with moderate renal impairment. Patients with moderate renal impairment may need a reduction of the dose. Caution and close monitoring of adverse reactions, particularly myelosuppression, is advised for patients with renal impairment. Patients with severe renal impairment (CrCL: <30 mL/min) were not evaluated (see ACTION AND CLINICAL PHARMACOLOGY – Special Populations and Conditions).

Male Patients:
Male patients with breast cancer have not been investigated in the pivotal clinical study. The effects of HALAVEN on human fertility are unknown. Testicular toxicity has been observed in rats and dogs (see TOXICOLOGY). Male patients should seek advice on conservation of sperm prior to treatment because of the possibility of irreversible infertility due to therapy with HALAVEN.

Monitoring and Laboratory Tests

Complete blood count (CBC) evaluation and liver function tests should be performed prior to each dose. The frequency of CBC monitoring should be increased in patients who develop Grade 3 or 4 cytopenias.
Electrolyte Monitoring:
HALAVEN has been associated with an increased incidence of hypokalemia. HALAVEN has also been associated with QT/QTc interval prolongation. Hypokalemia, hypocalcemia, and hypomagnesemia should be corrected prior to initiation of HALAVEN. Serum potassium, calcium, and magnesium should be monitored periodically during treatment.

ECG Monitoring:
ECG monitoring is recommended in patients with risk factors for torsade de pointes, such as patients with cardiac disease (e.g., congestive heart failure, bradyarrhythmias), and patients on concomitant medications that prolong the QT interval, especially Class IA or III antiarrhythmics, (see WARNINGS AND PRECAUTIONS, Cardiovascular; DRUG INTERACTIONS; ACTION AND CLINICAL PHARMACOLOGY, Electrocardiography).

ADVERSE REACTIONS

Adverse Drug Reaction Overview

The most common adverse reactions (≥25%) reported in patients receiving HALAVEN were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation.

The most common serious adverse reactions reported in patients receiving HALAVEN were febrile neutropenia (4%) and neutropenia (2%). The most common adverse reaction resulting in discontinuation of HALAVEN was peripheral neuropathy (5%). Development of severe peripheral neuropathy occurred in 8% of patients (Table 1). The most common adverse reactions leading to a clinical intervention were neutropenia, nausea, constipation, pyrexia, peripheral neuropathy, arthralgia/myalgia, anemia, back pain, headache and leukopenia.

Adverse reactions leading to discontinuation (HALAVEN = 13%, Treatment of Physician’s Choice = 15%) or dose reductions (HALAVEN = 17%, Treatment of Physician’s Choice = 16%) were comparable between the treatment groups.

Clinical Trial Adverse Drug Reactions

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

In the pivotal randomized, controlled EMBRACE study (Study 305), 762 patients were randomized (2:1) to receive either HALAVEN (1.4 mg/m² on Days 1 and 8 of a 21-day cycle) or single agent treatment chosen by their physician (control group). Of the randomized patients, 750 were treated. A total of 503 patients received HALAVEN and 247 patients in the control group received Treatment of Physician’s Choice (TPC). In the control group, 97% of patients received
chemotherapy (anthracyclines 10%, capecitabine 18%, gemcitabine 19%, taxanes 15%, vinorelbine 25%, other chemotherapies 10%) and 3% received hormonal therapy. The median duration of exposure was 118 days for patients receiving HALAVEN and 63 days for patients receiving control therapy.

Table 1 reports the most common non-hematologic adverse reactions for HALAVEN and TPC occurring in at least 10% of patients in the EMBRACE Study.

**Table 1: Non-hematologic Adverse Reactions with an Incidence of at Least 10% of Patients with Metastatic Breast Cancer (Safety Population) in the EMBRACE Study (Study 305)**

<table>
<thead>
<tr>
<th>MedDRA SOC and Preferred Term</th>
<th>HALAVEN n=503 (%)</th>
<th>Treatment of Physician’s Choice n=247 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any Event</td>
<td>Total Grade 3 Grade ≥ 4</td>
<td>Total Grade 3 Grade ≥ 4</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>35 1 0</td>
<td>28 3 0</td>
</tr>
<tr>
<td>Constipation</td>
<td>25 1 0</td>
<td>21 1 0</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>18 0 0</td>
<td>18 0 0</td>
</tr>
<tr>
<td>Vomiting</td>
<td>18 1 &lt;1</td>
<td>18 1 0</td>
</tr>
<tr>
<td>General disorders and</td>
<td></td>
<td></td>
</tr>
<tr>
<td>administrative site conditions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthenia/Fatigue b</td>
<td>54 9 1</td>
<td>40 11 1</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>21 &lt;1 0</td>
<td>13 &lt;1 0</td>
</tr>
<tr>
<td>Mucosal inflammation</td>
<td>9 1 0</td>
<td>10 2 0</td>
</tr>
<tr>
<td>Investigations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight decreased</td>
<td>21 1 NA</td>
<td>14 &lt;1 NA</td>
</tr>
<tr>
<td>Metabolism and nutrition</td>
<td></td>
<td></td>
</tr>
<tr>
<td>disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anorexia</td>
<td>20 1 0</td>
<td>13 1 0</td>
</tr>
<tr>
<td>Musculoskeletal and</td>
<td></td>
<td></td>
</tr>
<tr>
<td>connective tissue disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthralgia/Myalgia</td>
<td>22 &lt;1 0</td>
<td>12 1 0</td>
</tr>
<tr>
<td>Back pain</td>
<td>16 1 &lt;1</td>
<td>7 1 &lt;1</td>
</tr>
<tr>
<td>Bone pain</td>
<td>12 2 &lt;1</td>
<td>9 2 0</td>
</tr>
<tr>
<td>Pain in extremity</td>
<td>11 1 0</td>
<td>10 1 0</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peripheral neuropathy c</td>
<td>35 8 &lt;1</td>
<td>16 2 0</td>
</tr>
<tr>
<td>Headache</td>
<td>19 &lt;1 0</td>
<td>12 0 &lt;1</td>
</tr>
<tr>
<td>Respiratory, thoracic, and</td>
<td></td>
<td></td>
</tr>
<tr>
<td>mediastinal disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyspnea a</td>
<td>16 4 1</td>
<td>13 2 2</td>
</tr>
<tr>
<td>Cough</td>
<td>14 0 NA</td>
<td>9 0 NA</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

HALAVEN® (eribulin mesylate)
### Abnormal Hematologic and Clinical Chemistry Findings

Hematologic adverse reactions from the EMBRACE Study are reported in Table 2. Hematologic toxicities resulted in discontinuation in <1% of patients receiving HALAVEN. Febrile neutropenia occurred in 5% of patients receiving HALAVEN.

#### Table 2: Hematologic Adverse Reactions Among Patients with Metastatic Breast Cancer (Safety Population) in the EMBRACE Study (Study 305)

<table>
<thead>
<tr>
<th>Hematology Parameters</th>
<th>HALAVEN (n=503)</th>
<th>Treatment of Physician’s Choice (n=247)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Any Grade %</td>
<td>Grade 3 %</td>
</tr>
<tr>
<td>Leukopenia</td>
<td>88</td>
<td>31</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>82</td>
<td>29</td>
</tr>
<tr>
<td>Anemia</td>
<td>78</td>
<td>2</td>
</tr>
<tr>
<td>Lymphopenia</td>
<td>72</td>
<td>13</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>20</td>
<td>1</td>
</tr>
</tbody>
</table>

The neutropenia observed was generally reversible and not cumulative; the mean time to nadir within a cycle was approximately 13 days and the mean time to recovery from severe neutropenia (<500 cells/mm³) to neutropenia ≤ Grade 2 (≥1000 cells/mm³) was approximately 8 days.

The frequent laboratory abnormalities from the EMBRACE Study are reported in Table 3.
Table 3: Laboratory Abnormalities Among Patients with Metastatic Breast Cancer (Safety Population) in the EMBRACE Study (Study 305)

<table>
<thead>
<tr>
<th>Laboratory Abnormalities</th>
<th>HALAVEN (n=503)</th>
<th>Treatment of Physician’s Choice (n=247)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Any Grade</td>
<td>Grade 3</td>
</tr>
<tr>
<td>Aspartate Aminotransferase</td>
<td>73</td>
<td>5</td>
</tr>
<tr>
<td>Alanine Aminotransferase</td>
<td>61</td>
<td>3</td>
</tr>
<tr>
<td>Alkaline Phosphatase</td>
<td>58</td>
<td>5</td>
</tr>
<tr>
<td>Albumin</td>
<td>40</td>
<td>1</td>
</tr>
<tr>
<td>Hypokalemia</td>
<td>38</td>
<td>4</td>
</tr>
<tr>
<td>Hypocalcemia</td>
<td>35</td>
<td>1</td>
</tr>
<tr>
<td>Hypomagnesemia</td>
<td>34</td>
<td>2</td>
</tr>
<tr>
<td>Hyponatremia</td>
<td>32</td>
<td>3</td>
</tr>
<tr>
<td>Hypophosphatemia</td>
<td>23</td>
<td>6</td>
</tr>
<tr>
<td>Hypercalcemia</td>
<td>19</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Hyperkalemia</td>
<td>18</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Hypermagnesemia</td>
<td>17</td>
<td>4</td>
</tr>
<tr>
<td>Total Bilirubin</td>
<td>15</td>
<td>1</td>
</tr>
<tr>
<td>Creatinine</td>
<td>14</td>
<td>1</td>
</tr>
</tbody>
</table>

The safety profile of HALAVEN in the other Phase 2 and Phase 3 studies was consistent with that observed in the randomized, active-controlled EMBRACE Study (Study 305).

Less Common Clinical Trial Adverse Drug Reactions (>3% to <10%)

Blood and Lymphatic System Disorders: Febrile neutropenia

Ear and Labyrinth Disorders: Vertigo

Eye Disorders: Lacrimation increased

Cardiac Disorders: Tachycardia

Gastrointestinal Disorders: Abdominal distension, abdominal pain, abdominal pain upper, dyspepsia, dry mouth, stomatitis

General Disorders and Administration Site Conditions: Edema peripheral, pain

Infections and Infestations: Nasopharyngitis, rhinitis, urinary tract infection, upper respiratory tract infection

Investigations: Alanine aminotransferase increased, aspartate aminotransferase increased, weight increased

Metabolism and Nutrition Disorders: Decreased appetite, hyperglycemia, hypokalemia, hypomagnesemia

Musculoskeletal and Connective Tissue Disorders: Muscle spasms, muscular weakness, musculoskeletal chest pain, musculoskeletal pain

Nervous System Disorders: Dizziness, dysgeusia, hypoesthesia, lethargy

Psychiatric Disorders: Anxiety, depression, insomnina

Respiratory, Thoracic, and Mediastinal Disorders: Pharyngolaryngeal pain

Skin and Subcutaneous Tissue Disorder: Pruritus, rash

Vascular Disorders: Hypertension
Other serious adverse reactions in the 1,222 patients treated with HALAVEN not included above, and for which there is a possibility of a causal relationship to HALAVEN, include sudden death, pneumonia, sepsis (including neutropenic sepsis), dehydration, renal failure, pulmonary embolism, and deep vein thrombosis.

**Post-Market Adverse Drug Reactions**

The following adverse drug reaction has been identified during post-approval of HALAVEN. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

**Gastrointestinal Disorders**: Pancreatitis

**DRUG INTERACTIONS**

**Other QT/QTc Prolonging Drugs**

The concomitant use of Halaven with another QT/QTc-prolonging drug should be avoided to the extent possible. Drugs that have been associated with QT/QTc interval prolongation and/or torsade de pointes include, but are not limited to, the examples in the following list (Chemical/pharmacological classes are listed if some class members have been implicated in QT/QTc prolongation and/or torsade de pointes): Class IA antiarrhythmics, class III antiarrhythmics, class 1C antiarrhythmics; antipsychotics, antidepressants, opioids, macrolide antibiotics and analogues, quinolone antibiotics, antimalarials, azole antifungals, domperidone, 5-hydroxytryptamine (5-HT)₃ receptor antagonists, tyrosine kinase inhibitors, histone deacetylase inhibitors, beta-2 adrenoceptor agonists.

Caution should be observed if HALAVEN is used with drugs that can disrupt electrolyte levels, including, but not limited to, the following: loop, thiazide, and related diuretics; laxatives and enemas; amphotericin B; high dose corticosteroids.

Current information sources should be consulted for approved drugs that prolong the QT/QTc interval or cause electrolyte disturbances.

**Drug-Drug Interactions**

**Effects of CYP3A4 inhibitors and inducers on HALAVEN**

A pharmacokinetic (PK) study demonstrated that eribulin exposure (area under the curve and maximal concentration) was similar when HALAVEN was administered in combination with ketoconazole, a potent inhibitor of cytochrome P450 3A4 (CYP3A4), compared to administration of HALAVEN alone. A population PK analysis showed no effect of CYP3A4
inhibitors or inducers on eribulin exposure. Therefore, no drug-drug interactions are expected with CYP3A4 inhibitors or inducers.

Effects of transport protein inhibitors on HALAVEN

Non-clinical studies indicated that eribulin is a P-gp substrate (see DETAILED PHARMACOLOGY -Pharmacokinetics). A PK study demonstrated that eribulin exposure was similar when administered in combination with ketoconazole, an inhibitor of P-gp, compared to administration of eribulin alone. Eribulin is weakly metabolized and is mainly eliminated, unchanged, in feces and to a lower extent in urine. The contribution of P-gp to the biliary and renal excretion of eribulin is unknown. The transport proteins involved in the excretion of eribulin have not been identified but inhibition of transport proteins could in theory give rise to increased exposure to eribulin. Caution should be exercised when HALAVEN is administered with inhibitors of transport proteins.

Effects of HALAVEN on Other Drugs

Eribulin does not inhibit CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4 or induce CYP1A2, CYP2C9, CYP2C19, or CYP3A4 enzymes at relevant clinical concentrations and is not expected to alter the plasma concentrations of other drugs that are substrates of these enzymes.

Drug-Lifestyle Interactions

No studies on the effects of HALAVEN on the ability to drive or use machines have been performed. HALAVEN may cause side effects such as tiredness (fatigue) and dizziness, which may lead to a minor or moderate influence on the ability to drive or use machines. Patients should be advised not to drive and/or use machinery if they feel tired or dizzy.

DOSAGE AND ADMINISTRATION

Recommended Dose and Dosage Adjustment

General Dosing Information
The recommended dose of HALAVEN is 1.4 mg/m² administered intravenously (IV) over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.

Patients should have Absolute Neutrophil Count (ANC) values ≥1,500 cells/mm³ and platelets >100,000/mm³ at the initiation of treatment with HALAVEN.

Premedication with steroids and/or antihistamines to prevent hypersensitivity reactions is not required with the use of HALAVEN. No special tubing is required for the IV administration of HALAVEN.
Dosage Adjustment During Treatment
Assess for peripheral neuropathy and obtain complete blood cell counts prior to each dose.

Recommended dose delays

Do not administer HALAVEN on Day 1 or Day 8 for any of the following:
- ANC < 1,000/mm³
- Platelets < 75,000/mm³
- Grade 3 or 4 non-hematological toxicities

The Day 8 dose may be delayed for a maximum of 1 week
- If toxicities do not resolve or improve to ≤ Grade 2 severity by Day 15, omit the dose.
- If toxicities resolve or improve to ≤ Grade 2 severity by Day 15, administer HALAVEN at a reduced dose and initiate the next cycle no sooner than 2 weeks later.

Recommended dose reductions

If a dose has been delayed for toxicity and toxicities have recovered to Grade 2 severity or less, resume HALAVEN at a reduced dose as set out in Table 4.

Do not re-escalate HALAVEN dose after it has been reduced.

Table 4: Dose Adjustment Recommendations

<table>
<thead>
<tr>
<th>Event Description</th>
<th>Recommended HALAVEN Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Permanently reduce the 1.4 mg/m² HALAVEN dose for any of the following:</td>
<td></td>
</tr>
<tr>
<td>ANC &lt;500 cells/mm³ lasting &gt;7 days</td>
<td>1.1 mg/m²</td>
</tr>
<tr>
<td>ANC &lt;1,000 cells/mm³ with fever or infection</td>
<td></td>
</tr>
<tr>
<td>Platelets &lt;25,000/mm³</td>
<td></td>
</tr>
<tr>
<td>Platelets &lt;50,000/mm³ requiring transfusion</td>
<td></td>
</tr>
<tr>
<td>Non-hematologic Grade 3 or 4 toxicities</td>
<td></td>
</tr>
<tr>
<td>Omission or delay of Day 8 HALAVEN dose in previous cycle for toxicity</td>
<td></td>
</tr>
</tbody>
</table>

| Occurrence of any event requiring permanent dose reduction while receiving 1.1 mg/m² | 0.7 mg/m² |
| Occurrence of any event requiring permanent dose reduction while receiving 0.7 mg/m² | Discontinue HALAVEN |

ANC= absolute neutrophil count.
Toxicities graded in accordance with National Cancer Institute (NCI) Common Terminology Criteria for Adverse Reactions (CTCAE) version 3.0.

Re-treatment criteria: Patients should only be re-treated with HALAVEN when absolute neutrophil count (ANC) is ≥1,000 cells/mm³, platelets are ≥75,000/mm³, and any other toxicity of a previous cycle has recovered to Grade ≤2 (except anemia).
Dosage Adjustment in Special Populations – Hepatic Impairment

The recommended dose for patients with mild hepatic impairment (Child-Pugh A) is 1.1 mg/m² administered IV on Days 1 and 8 of a 21-day cycle. The recommended dose for patients with moderate hepatic impairment (Child Pugh B) is 0.7 mg/m² administered IV on Days 1 and 8 of a 21-day cycle. HALAVEN was not studied in patients with severe hepatic impairment (Child-Pugh C); therefore, the use of HALAVEN is not recommended in these patients.

Administration

HALAVEN is a sterile, ready-to-use, clear, colorless aqueous solution for IV administration. Each vial contains 1 mg of eribulin mesylate as a 0.5 mg/mL solution in ethanol:water (5:95).

HALAVEN solution should be aseptically withdrawn from the vial into a syringe and administered IV without dilution. Alternatively, HALAVEN may be diluted in up to 100 mL 0.9% sodium chloride. HALAVEN must not be mixed with other medicinal products.

HALAVEN should not be diluted or administered through an intravenous line containing solutions with dextrose.

HALAVEN is administered intravenously over 2 to 5 minutes.

No special tubing is required for the IV administration of HALAVEN.

Good peripheral venous access or a patent central line should be ensured before administration. There is no evidence that eribulin mesylate is a vesicant or an irritant. In the event of extravasation, treatment should be symptomatic.

Parenteral solution should be inspected visually for clarity, particulate matter, precipitation, discoloration, leakage etc. prior to administration. Only clear solution without particles, precipitate or discoloration or leakage should be used. Unused portion should be discarded.

OVERDOSEAGE

One case of overdose of HALAVEN has been reported. The patient inadvertently received 8.6 mg of HALAVEN (approximately 4 times the planned dose) and subsequently developed a hypersensitivity reaction (Grade 3) on Day 3 and neutropenia (Grade 3) on Day 7. Both adverse reactions resolved with supportive care.

There is no known antidote for HALAVEN overdose. In the event of an overdose, the patient should be closely monitored. Management of overdose should include supportive medical interventions to treat the presenting clinical manifestations.

For management of a suspected drug overdose, consult the regional Poison Control Centre immediately.
ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

Eribulin is a non-taxane microtubule dynamics inhibitor belonging to the halichondrin class of antineoplastic agents. Eribulin inhibits the growth phase of microtubule dynamics without affecting the shortening phase and sequesters tubulin into nonproductive aggregates. Eribulin exerts its anticancer effects via a tubulin-based antimitotic mechanism leading to G2/M cell-cycle block, disruption of mitotic spindles, and, ultimately, apoptotic cell death after prolonged mitotic blockage.

Pharmacodynamics

Eribulin has in vivo antitumor activity in multiple human tumor xenografts in athymic nude mice.

Electrocardiography
The effect of HALAVEN on the electrocardiographic QT interval was assessed in an open-labelled, uncontrolled, multicentre, single-arm study in 26 patients with solid tumors who received treatment with 1.4 mg/m² on Day 1 and Day 8 of a 21-day cycle. No effect on the QTc interval was observed on Day 1. On day 8 of treatment, QTc interval prolongation was evident. The largest mean increase from baseline was 10.5 msec (90% CI 4.9 to 16.2). The exposure to HALAVEN was similar on Day 1 and Day 8; therefore, differences in plasma concentration could not account for the delayed increase in the QTc interval.

Pharmacokinetics

The pharmacokinetics of eribulin is linear over the dose range of 0.25 mg/m² to 4.0 mg/m². Following 1.4 mg/m² dose administration, the mean maximum plasma concentration (Cmax) ranged from 186 to 519 ng/mL and the mean exposure (AUC) ranged from 600 to 971 ng·hr/mL.

Distribution:
The pharmacokinetics of eribulin is characterized by a rapid distribution phase followed by a prolonged elimination phase, with a mean terminal half-life of approximately 40 hours. It has a large volume of distribution (43 to 114 L/m²) and low clearance (1.16 to 2.42 L/hr/m²). Eribulin exposure after multiple dosing is comparable to that following a single dose. No significant accumulation of eribulin is observed on weekly administration.

The plasma protein binding of eribulin is low. At 100 to 1,000 ng/mL eribulin, the protein binding of eribulin ranges from 49% to 65% in human plasma.

Metabolism:
Cytochrome P450 3A4 (CYP3A4) negligibly metabolizes eribulin in vitro. Eribulin inhibits CYP3A4 activity in human liver microsomes, but it is unlikely that eribulin will substantially
increase the plasma levels of CYP3A4 substrates. Eribulin shows no induction potential for CYP1A, CYP2C9, CYP2C19, and CYP3A in primary human hepatocytes. No significant inhibition of CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP2E1 was detected with eribulin concentrations up to 5 μM in pooled human liver microsomes. No significant inhibition of CYP3A4 was detected with eribulin concentrations up to 1μM (730 ng/mL) in pooled liver microsomes. Therefore, it is unlikely that eribulin will affect plasma levels of drugs that are substrates of CYP enzymes.

Unchanged eribulin was the major circulating species in plasma following administration of 14C-eribulin to patients. Metabolite concentrations represented <0.6% of parent compound, confirming that there are no major human metabolites of eribulin.

**Excretion:**
Eribulin is eliminated primarily in feces unchanged. After administration of 14C-eribulin to patients, approximately 82% of the dose was eliminated in feces and 9% in urine, indicating that renal clearance is not a significant route of eribulin elimination. Unchanged eribulin accounted for approximately 88% and 91% of the radioactive materials recovered in feces and urine respectively. Eribulin is a substrate of the drug efflux transporter P-gp *in vitro*.

**Special Populations and Conditions**

**Effects of Age, Gender, and Race**
Based on a population pharmacokinetic analysis, gender, race, and age do not have a significant effect on the pharmacokinetics of eribulin.

**Effects of Hepatic Impairments**
A Phase 1 study evaluated the pharmacokinetics of eribulin in patients with mild (Child-Pugh A, n=7) and moderate (Child-Pugh B, n=4) hepatic impairment. Compared to patients with normal hepatic function (n=6), exposure to eribulin increased 1.75-fold and 2.79-fold in patients with mild and moderate hepatic impairment, respectively. Administration of HALAVEN at a dose of 1.1 mg/m² and 0.7 mg/m² to patients with mild and moderate hepatic impairment respectively resulted in similar exposure to eribulin as a dose of 1.4 mg/m² to patients with normal hepatic function. Dose reduction to 1.1 mg/m² is recommended for patients with mild (Child-Pugh A) and to 0.7 mg/m² for patients with moderate hepatic impairment (Child-Pugh B). HALAVEN was not studied in patients with severe hepatic impairment (Child-Pugh C).

**Effects of Renal Impairments**
Eribulin is minimally excreted via the kidney. No formal pharmacokinetics studies were conducted with HALAVEN in patients with renal impairment. However, based on a population pharmacokinetics analysis, mild (creatinine clearance, CrCl: 50-80 mL/min) or moderate renal impairment (CrCl: 30-50 mL/min) could cause decrease in clearance and up to 2-fold increase in exposure to eribulin in patients with moderate renal impairment. Patients with moderate renal impairment may need a reduction of the dose. Caution and close monitoring of adverse reactions, particularly myelosuppression, is advised for patients with renal impairment. Patients with severe renal impairment (CrCL: <30 mL/min) were not evaluated in the study.
STORAGE AND STABILITY

Store the vials in their original cartons. Store up to 25°C with excursions permitted to 30°C. Do not freeze.

Once withdrawn from the vial into a syringe, HALAVEN (0.5 mg/mL) may be stored for up to 6 hours at ambient temperature and lighting or up to 24 hours under refrigeration. Diluted solutions of HALAVEN (0.005 to 0.2 mg/mL in normal saline) may be stored for up to 48 hours refrigerated or for up to 24 hours at ambient temperature and lighting. Any unused portions of the vial should be discarded.

Diluted solutions of HALAVEN (0.005 to 0.2 mg/mL in normal saline) are compatible with IV bags for up to 48 hours, refrigerated or for up to 24 hours at ambient temperature and lighting.

SPECIAL HANDLING INSTRUCTIONS

Procedures for proper handling and disposal of anticancer drugs should be followed. There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate (ASHP guidelines 2006, OSHA Manual (Section VI, Chapter 2) 1999, Polovich et al. 2005, and NIOSH Alert 2004).

DOSAGE FORMS, COMPOSITION AND PACKAGING

HALAVEN (eribulin mesylate injection) is a sterile, clear, colorless solution in a single use vial, one vial per carton. The drug product contains 1.0 mg eribulin mesylate per vial in 2 mL of solution. The eribulin mesylate solution concentration is 0.5 mg/mL.

Inactive ingredients: dehydrated alcohol USP (5% v/v), hydrochloric acid (for pH adjustment), sodium hydroxide (for pH adjustment), water for injection USP (95% v/v).
PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Common name: eribulin mesylate


Molecular formula and molecular mass:

Molecular formula: C_{40}H_{59}NO_{11} \cdot CH_{4}SO_{3}

Molecular weight: 826.0 (729.9 for free base)

Structural formula:

![Chemical structure of eribulin mesylate]

Physicochemical properties: White powder and freely soluble in water, methanol, ethanol, 1-octanol, benzyl alcohol, dimethylsulfoxide, N-methylpyrrolidone, dichloromethane and ethylacetate, soluble in acetone, sparingly soluble in acetonitrile, practically insoluble in tert-butylmethyl ether, n-heptane and n-pentane. In Britton-Robinson buffer, eribulin mesylate was freely soluble at pH 3-7, soluble at pH 9 and slightly soluble at pH 11.
CLINICAL TRIALS

In an open-label, randomized, multicenter, multinational study of 762 patients with metastatic breast cancer (EMBRACE Study - Table 5), the efficacy and safety of HALAVEN were assessed in patients previously treated with a minimum of 2 and a maximum of 5 prior chemotherapy regimens (at least 2 for locally recurrent or metastatic disease), including an anthracycline and a taxane (unless contraindicated). Patients received a median of 4 prior chemotherapy regimens. Patients must have progressed within 6 months of their last chemotherapeutic regimen. Patients with pre-existing peripheral neuropathy Grade ≤2 were enrolled. Patients were randomized 2:1 to receive HALAVEN (1.4 mg/m² on Days 1 and 8 in a 21-day cycle administered IV over 2 to 5 minutes) or Treatment of Physician’s Choice, defined as any single-agent chemotherapy, hormonal treatment, or biologic therapy approved for the treatment of cancer; or palliative treatment or radiotherapy, administered according to local practice, if applicable. The Treatment of Physician’s Choice arm consisted of chemotherapy for 97% of patients or hormonal therapy for 3% of patients. Patients were treated with a median of 5 cycles (range, 1 to 23 cycles) of HALAVEN therapy. The median relative dose intensity for HALAVEN was 91%.

Patient characteristics were well balanced across treatment arms. Select baseline patient and disease characteristics are summarized in Table 5.

Sixty-four percent of patients were enrolled from North America/Western Europe/Australia, 25% from Eastern Europe/Russia, and 11% from Latin America/South Africa.

Table 5: Patient and Baseline Disease Characteristics (ITT Population)

<table>
<thead>
<tr>
<th>Patient Characteristic</th>
<th>HALAVEN (n=508)</th>
<th>Treatment of Physician’s Choice (n=254)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (range)</td>
<td>55 (28-85)</td>
<td>56 (27-81)</td>
</tr>
<tr>
<td><strong>Age (years) distribution, n (%)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;40</td>
<td>34 (7)</td>
<td>17 (7)</td>
</tr>
<tr>
<td>≥40 to &lt;65</td>
<td>380 (75)</td>
<td>180 (71)</td>
</tr>
<tr>
<td>≥65 to ≤75</td>
<td>86 (17)</td>
<td>51 (20)</td>
</tr>
<tr>
<td>&gt;75</td>
<td>8 (2)</td>
<td>6 (2)</td>
</tr>
<tr>
<td><strong>Race, n (%)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>20 (4)</td>
<td>14 (6)</td>
</tr>
<tr>
<td>White</td>
<td>470 (93)</td>
<td>233 (92)</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>3 (1)</td>
<td>2 (1)</td>
</tr>
<tr>
<td>Other</td>
<td>15 (3)</td>
<td>5 (2)</td>
</tr>
<tr>
<td><strong>ECOG performance status, n (%)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>217 (43)</td>
<td>103 (41)</td>
</tr>
<tr>
<td>1</td>
<td>244 (48)</td>
<td>126 (50)</td>
</tr>
<tr>
<td>2</td>
<td>39 (8)</td>
<td>22 (9)</td>
</tr>
<tr>
<td>Not reported</td>
<td>8 (2)</td>
<td>3 (1)</td>
</tr>
<tr>
<td><strong>Estrogen receptor status, n (%)</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

HALAVEN® (eribulin mesylate)
<table>
<thead>
<tr>
<th>Patient Characteristic</th>
<th>HALAVEN (n=508)</th>
<th>Treatment of Physician’s Choice (n=254)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
<td>336 (66)</td>
<td>171 (67)</td>
</tr>
<tr>
<td>Negative</td>
<td>143 (28)</td>
<td>72 (28)</td>
</tr>
<tr>
<td>Unknown</td>
<td>29 (6)</td>
<td>11 (4)</td>
</tr>
<tr>
<td>Progesterone receptor status, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>254 (50)</td>
<td>123 (48)</td>
</tr>
<tr>
<td>Negative</td>
<td>197 (39)</td>
<td>102 (40)</td>
</tr>
<tr>
<td>Unknown</td>
<td>57 (11)</td>
<td>29 (11)</td>
</tr>
<tr>
<td>HER2 receptor status, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>83 (16)</td>
<td>40 (16)</td>
</tr>
<tr>
<td>Negative</td>
<td>373 (73)</td>
<td>192 (76)</td>
</tr>
<tr>
<td>Unknown</td>
<td>52 (10)</td>
<td>22 (9)</td>
</tr>
<tr>
<td>ER-, PR-, HER2-, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of prior chemotherapy regimens, n (%)</td>
<td>93 (18)</td>
<td>51 (20)</td>
</tr>
<tr>
<td>1 Regimen</td>
<td>1 (&lt;1)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>2 Regimens</td>
<td>65 (13)</td>
<td>31 (12)</td>
</tr>
<tr>
<td>3 Regimens</td>
<td>176 (35)</td>
<td>83 (33)</td>
</tr>
<tr>
<td>4 Regimens</td>
<td>166 (33)</td>
<td>79 (31)</td>
</tr>
<tr>
<td>5 Regimens</td>
<td>85 (28)</td>
<td>51 (20)</td>
</tr>
<tr>
<td>&gt;6 Regimens</td>
<td>13 (3)</td>
<td>9 (4)</td>
</tr>
<tr>
<td>Sites of involvement</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>296 (59)</td>
<td>159 (63)</td>
</tr>
<tr>
<td>Lung</td>
<td>197 (39)</td>
<td>95 (37)</td>
</tr>
<tr>
<td>Bone</td>
<td>306 (60)</td>
<td>158 (62)</td>
</tr>
<tr>
<td>Number of sites of metastases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤2 sites of metastases</td>
<td>257 (51)</td>
<td>117 (46)</td>
</tr>
<tr>
<td>≥2 sites of metastases</td>
<td>249 (49)</td>
<td>137 (54)</td>
</tr>
</tbody>
</table>

Abbreviations: ECOG, Eastern Cooperative Oncology Group, ER, estrogen receptor, HER2, human epidermal growth factor receptor 2, PR, progesterone receptor

The primary endpoint of the study was overall survival. A statistically significant improvement in overall survival was observed in patients randomized to HALAVEN compared to Treatment of Physician’s Choice (Table 6). An improvement of 2.5 months median survival (HR 0.809, 95% CI: 0.660, 0.991, p=0.041) was demonstrated. The 1-year survival rates were 54% (95% CI: 0.492, 0.586) in patients randomized to HALAVEN and 44% (95% CI: 0.371, 0.502) in the Treatment of Physician’s Choice group. An updated survival analysis, conducted when 77% of events had been observed (Figure 1), was consistent with the primary analysis with an improvement in median overall survival of 2.6 months (HR 0.805, 95% CI: 0.677, 0.958, nominal p=0.014) observed in patients randomized to HALAVEN compared to Treatment of Physician’s Choice. In patients randomized to HALAVEN, the objective response rate by the RECIST criteria was 11% (95% CI: 8.6%, 14.3%) and the median response duration was 4.2 months (95% CI: 3.8, 5.0 months).
Table 6: Comparison of Overall Survival: HALAVEN vs Treatment of Physician’s Choice—ITT Analysis

<table>
<thead>
<tr>
<th>Efficacy Parameter</th>
<th>HALAVEN</th>
<th>Treatment of Physician’s Choice</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n=508)</td>
<td>(n=254)</td>
</tr>
<tr>
<td><strong>Overall Survival</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of deaths</td>
<td>274</td>
<td>148</td>
</tr>
<tr>
<td>Median, months (95% CI)</td>
<td>13.1 months (11.8, 14.3)</td>
<td>10.6 months (9.3, 12.5)</td>
</tr>
<tr>
<td>Hazard Ratio (95% CI)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.809&lt;sup&gt;b&lt;/sup&gt; (0.660, 0.991)</td>
<td></td>
</tr>
<tr>
<td><strong>P value&lt;sup&gt;c&lt;/sup&gt;</strong></td>
<td></td>
<td>0.041</td>
</tr>
</tbody>
</table>

**Updated survival analysis**

|                        |             |                                 |
| Number of deaths       | 386         | 203                             |
| Median, months (95% CI)| 13.2 (12.1, 14.4) | 10.6 (9.2, 12.0)               |
| Hazard Ratio (95% CI)<sup>a</sup> | 0.805 (0.677, 0.958) |                                 |
| **P value<sup>c</sup>** |             | 0.014                           |

Abbreviations: CI, confidence interval; HER2, human epidermal growth factor receptor 2; ITT, intent to treat.

<sup>a</sup> Based on a Cox proportional hazards model stratified by geographic region, HER2 status, and prior capecitabine therapy.

<sup>b</sup> For the hazard ratio, a value less than 1.00 favors treatment with HALAVEN.

<sup>c</sup> Based on a log-rank test stratified by geographic region, HER2 status, and prior capecitabine therapy.
DETAILED PHARMACOLOGY

Animal

Pharmacodynamics
Results of in vitro studies demonstrate that addition of eribulin mesylate inhibits cell growth with sub- to low-nmol/L half-maximal inhibitory concentration (IC₅₀) values in a wide range of established human cancer cell lines, including breast, colon, prostate, ovarian, small cell lung, and non-small cell lung cancers, as well as histiocytic lymphoma, promyelocytic leukemia, pharyngeal squamous cell (head and neck cancer) carcinoma, melanoma and uterine sarcoma. Eribulin mesylate exerts its anticancer effects via a tubulin-based antimitotic mechanism, leading to G₂/M (Gap 2/mitosis stages of cell cycle) cell cycle blocks, disruption of mitotic spindles, and ultimately apoptotic cell death after prolonged mitotic blockage. Eribulin mesylate leads to inhibition of microtubule growth and formation of non-productive tubulin aggregates, but without effects on microtubule shortening.

Eribulin mesylate retained undiminished in vitro activity against a cancer cell line that was taxane-resistant due to β-tubulin mutations. Eribulin mesylate is a substrate for the P-gp drug efflux pump, and showed reduced in vitro potency against a human cancer cell line expressing P-gp.
Electrophysiological Systems
Intravenous infusion over 1 hour of eribulin mesylate at 0.04 mg/kg (0.8 mg/m²) in dogs resulted in transiently decreased systolic, diastolic and mean arterial pressure and heart rate, and increased RR interval but no effects on other ECG parameters were observed for up to 8 hours post-dose. The estimated maximal plasma concentrations achieved in the cardiovascular safety pharmacology studies were approximately 6% of the clinical C_{max}.

Evaluation of potential cardiac effects in vitro were conducted at concentrations far exceeding (>300 times) the clinical C_{max} concentrations. In vitro, eribulin at concentrations up to 30 μmol/L did not inhibit hERG activity in stably transfected HEK293 cells and had no effects on the cardiac action potential parameters in isolated dog Purkinje fibers.

Central Nervous System and Respiratory Systems
Administration of eribulin mesylate by a slow bolus intravenous injection at 0.1 or 0.25 mg/kg produced no notable effects on the central nervous or respiratory systems in male rats.

Pharmacokinetics
Eribulin is eliminated primarily by biliary excretion. The transport protein involved in the excretion is presently unknown. Preclinical studies indicate that eribulin is transported by P-gp. However, it is unknown whether P-gp is contributing to the biliary excretion of eribulin.

TOXICOLOGY

Repeated-dose Toxicity
Intravenous repeated-dose toxicity studies were conducted in F344 rats and beagle dogs. In these studies, eribulin mesylate was administered three times with 4-day (Q4D×3) or 7-day (Q7D×3) intervals. In the 6-month chronic toxicity studies in rats and dogs, the dosing schedule of Q7D×3 followed by a 14-day recovery period was repeated in six cycles. In these studies, eribulin mesylate was administered to rats by slow bolus injection and to dogs as a 1-hour intravenous infusion. The dose-limiting toxicity precluded administration on a repeated basis of doses exceeding the clinical recommended dose (1.4 mg/m² of eribulin mesylate administered IV over 2 to 5 minutes). At the doses that could be administered, plasma concentrations in animals were lower than the clinical exposure.

The antiproliferative activity of eribulin mesylate was associated with bone marrow, lymphoid and testicular toxicity in all of the Q4D×3 and Q7D×3 repeated-dose toxicity studies in both rats and dogs. In dogs, emesis, diarrhea as well as necrosis and hyperplasia in the crypts/glands of the small and large intestine occurred at lethal doses (0.075 mg/kg [1.5 mg/m²] Q4D×2). Bone marrow toxicity and/or gastro-intestinal toxicity appeared to be the dose-limiting toxicity of eribulin mesylate. Bone marrow toxicity included a decreased number of hematopoietic cells, resulting in reduced peripheral blood cell counts and histologically visible bone marrow hypocellularity. These bone marrow alterations were often accompanied by compensatory extramedullary hematopoiesis in the spleen. The lowest doses at which bone marrow toxicity appeared in the repeated-dose toxicity studies were 0.05 mg/kg (0.30 mg/m²) in rats and 0.03
mg/kg (0.60 mg/m²) in dogs. Lymphoid toxicity, represented by a decreased circulating lymphocyte count and/or atrophy of the lymphoid organs was noted at doses of ≥0.60 mg/m² (≥0.10 mg/kg in rats and ≥0.03 mg/kg in dogs) in the Q7D×3 and Q4D×3 studies. Bone marrow and lymphoid toxicity were reversible, with recovery underway or completed within 26 days post-dosing during the post-dosing observation period in the Q4D×3 and Q7D×3 toxicity studies, in both rats and dogs. Testicular toxicity included the macroscopic findings of soft and/or small testes and decreased testicular weight. Histological observations in the testes included hypocellularity or degeneration of the seminiferous tubules. These changes were associated with secondary epididymal hypospermia/aspermia. Testicular toxicity occurred at ≥0.05 mg/kg (0.30 mg/m²) in rats and 0.045 mg/kg (0.90 mg/m²) in dogs. In the rat, testicular degeneration noted at necropsy was generally more severe 14 to 26 days after the last dose than 3 days post dose. This may be related to the failure of the damaged cells to divide and suggests that the testicular damage may be irreversible. It may also be a reflection of insufficient recovery time since the duration of the spermatogenic cycle in rats is 48-52 days.

Degeneration of myocytes and neurofiber degeneration of the sciatic nerve were also observed in rats at doses of ≥0.20 mg/kg (1.20 mg/m²) in the Q4D×3 and Q7D×3 studies, respectively. These effects may appear as neuropathy and/or myalgia in humans. Although degeneration of myocytes disappeared by Day 35 (26 days post dose), fiber degeneration of sciatic nerve was still present on Day 29 (14 days post dose). There was one male rat at the high dose (0.15 mg/kg [0.90 mg/m²]) in the chronic toxicity study with neurofiber degeneration. Six month studies (Q7Dx3 IV administration followed by 14 non-dosing days for 6 cycles) did not identify any unexpected toxicity at the dose administered (up to 0.90 mg/m² in rats and dogs). Focal and multifocal necrosis in the liver of male rats in the chronic rat study were attributed to bacterial infections and considered secondary to the effects of eribulin on bone marrow.

**Genotoxicity**
Eribulin mesylate was non-mutagenic in the Ames test, both with and without exogenous metabolizing system (S9). Eribulin mesylate was weakly positive in the mouse lymphoma tk assay in both activated and non-activated cultures. In the in vivo rat micronucleus assay, eribulin mesylate showed some evidence of genotoxic activity, forming substantially larger micronuclei than those seen with cyclophosphamide. The generally large-sized micronuclei induced by eribulin mesylate were consistent with interference or disruption of chromosome segregation rather than to a clastogenic action resulting in chromosome breakage.

**Reproductive and Developmental Toxicity**
The effects of eribulin mesylate on pregnancy and embryo-fetal development were evaluated by intermittent administration during the mid-organogenesis period in rats. The dose of 0.10 mg/kg (0.60 mg/m²) and higher exhibited embryo-fetal lethality with reduced fetal body weight. The dose of 0.15 mg/kg (0.90 mg/m²) induced external and/or soft tissue anomalies (absence of lower jaw, tongue, stomach and spleen) and early delivery.

**Other Toxicity Studies**
In vitro myelotoxicity studies were performed in bone marrow cells (CFU-GM) of mouse, dog and human using Hipple’s soft agar assay. Bone marrow cells were incubated with eribulin
mesylate at concentrations of 0, 0.01, 0.1, 1, 10 and 100 nmol/L. The inhibition of CFU-GM colony formation was measured, and the concentrations that caused inhibition of colony formation were calculated by a regression analysis where possible. The mean IC90 were 63.1, 19.8, and 21.85 nmol/L in mice, dogs, and human, respectively.

Similar in vitro HALO (hemotoxicity assays via luminescence output) studies were performed with bone marrow multipotential stem cells (CFC-GEMM) of mouse, dog and human. Bone marrow cells were incubated with eribulin mesylate and comparators (paclitaxel and vinblastine) at concentrations of 0.1 to 1000 nmol/L. The murine CFC-GEMM cells appeared to be less sensitive to the antiproliferative effects of eribulin mesylate, whereas human and canine cells appeared to be equally sensitive. The IC50 values of eribulin mesylate were 148, 11.4 and 15.9 nmol/L in mice, dogs and human, respectively. Species sensitivity to eribulin mesylate-caused toxicity can be ranked as follows: dog ≥ human > mouse.
REFERENCES


http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html


Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings. NIOSH Alert 2004;165.

PART III: CONSUMER INFORMATION

This leaflet is part III of a three-part "Product Monograph" published when HALAVEN was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about HALAVEN. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

What the medication is used for:
HALAVEN (HAL-ih-ven) is a prescription cancer medicine.
HALAVEN is used to treat patients with breast cancer that has spread to other parts of the body.
HALAVEN is used for patients who have already received at least two other types of anticancer medicines for the treatment of breast cancer that has spread.

What it does:
HALAVEN is an anti-cancer agent which works by stopping the growth of cancer cells.

When it should not be used:
Do not use HALAVEN if you are allergic to eribulin mesylate, or halichondrin B, or any drug related to halichondrin B.

What the medicinal ingredient is:
Eribulin mesylate

What the non-medicinal ingredients are:
Alcohol, hydrochloric acid, sodium hydroxide, water for injection.

What dosage forms it comes in:
HALAVEN contains 1.0 mg eribulin mesylate per vial in 2 mL of solution.

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions
HALAVEN should be prescribed and managed by a doctor experienced in the use of cancer drugs. Serious side effects with HALAVEN include:
• Neutropenia (decrease in the number of white blood cells)
• Abnormal electrical signal of the heart called "prolongation of the QT interval" (changes in heartbeat)
• HALAVEN has not been studied in patients with severe hepatic (liver) or renal (kidney) impairment.

BEFORE you use HALAVEN talk to your doctor or pharmacist about all of your medical conditions, including if you:
• have low white blood cell counts or low platelet levels
• have a fever (temperature above 38.1°C) or an infection
• have heart problems including an abnormal electrical signal of the heart called "prolongation of the QT interval" (changes in heartbeat)
• experience numbness, tingling or burning in your hands and feet
• have liver or kidney problems
• are pregnant or plan to become pregnant. You should not receive HALAVEN during pregnancy because it may harm your unborn baby. Talk with your health professional about how to prevent pregnancy while receiving HALAVEN. Tell your health professional right away if you become pregnant or think you are pregnant while receiving HALAVEN
• are breast feeding. It is not known if HALAVEN passes into breast milk. Breast feeding must be avoided.

HALAVEN may cause drowsiness or tiredness. Do not drive or operate machinery until you know how the medication affects you.

The safety and effectiveness of HALAVEN in patients under 18 years of age have not been established.

INTERACTIONS WITH THIS MEDICATION

Tell your doctor before taking HALAVEN if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.

HALAVEN may interact with the following medications;
• drugs known to prolong the QT/QTc interval and/or cause torsade de points
• drugs that decrease electrolyte levels

PROPER USE OF THIS MEDICATION

Usual dose: 1.4 mg/m² body surface area given as an injection into the vein over 2 to 5 minutes on Days 1 and 8 of a 21-day treatment cycle.

During treatment with HALAVEN, you may also need to have other tests including blood tests.
Overdose:
In case of drug overdose, contact a health professional, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Possible side effects with the use of HALAVEN include:

**Very common side effects (≥10%)**
- low white or red blood cell count
- weakness or tiredness
- hair loss
- numbness, tingling, or burning in your hands and feet (neuropathy)
- nausea, vomiting, and constipation, or diarrhea
- fever
- muscle or joint pain, bone pain
- headache
- eating disorder (anorexia)
- lost weight
- shortness of breath
- cough

**Common side effects (<10%)**
- inflammation of the mucosal lining of the mouth
- dizziness, vertigo
- swelling of hands and feet or limbs (edema peripheral)
- skin rash, itchiness
- abdominal pain
- high blood pressure
- anxiety, depression, trouble sleeping
- changes in heart beat (prolongation of the QT interval)

**Rare side effects (<0.1%)**
- pancreatitis (inflammation of the pancreas)

Tell your health professional about any side effect that bothers you or that does not go away.

These are not all the possible side effects with HALAVEN. For more information, ask your health professional.

### SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Talk with your doctor or pharmacist</th>
<th>Stop taking drug and call your doctor or pharmacist</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Very Common</strong> (≥ 10%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tiredness</td>
<td>Only if severe</td>
<td>In all cases</td>
</tr>
<tr>
<td>Hair loss</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>Nausea, vomiting, constipation</td>
<td>√</td>
<td></td>
</tr>
<tr>
<td>Numbness, tingling, or burning in hands and feet</td>
<td></td>
<td>√</td>
</tr>
<tr>
<td>Diarrhea</td>
<td></td>
<td>√</td>
</tr>
<tr>
<td>Signs of infection (fever, chills, cough, burning or pain when urinating)</td>
<td></td>
<td>√</td>
</tr>
<tr>
<td><strong>Common</strong> (&lt;10%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Swelling of hands, feet, or limbs</td>
<td></td>
<td>√</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td></td>
<td>√</td>
</tr>
<tr>
<td>Muscle spasms or weakness</td>
<td></td>
<td>√</td>
</tr>
<tr>
<td>Changed heart beat (prolongation of the QT interval)</td>
<td></td>
<td>√</td>
</tr>
<tr>
<td><strong>Rare</strong> (&lt;0.1%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pancreatitis (inflammation of the pancreas)</td>
<td></td>
<td>√</td>
</tr>
</tbody>
</table>

*frequency from postmarketing reports

This is not a complete list of side effects. For any unexpected effects while taking HALAVEN, contact your doctor or pharmacist.

**HOW TO STORE IT**

Store up to 25°C. Excursions permitted to 30°C. Do not freeze.
REPORTING SUSPECTED SIDE EFFECTS

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

- Report online at www.healthcanada.gc.ca/medeffect
- Call toll-free at 1-866-234-2345
- Complete a Canada Vigilance Reporting Form and:
  - Fax toll-free to 1-866-678-6789, or
  - Mail to: Canada Vigilance Program
    Health Canada
    Postal Locator 0701D
    Ottawa, Ontario
    K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at www.healthcanada.gc.ca/medeffect.

NOTE: Should you require information related to the management of the side effect, contact your health professional. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be found by contacting the sponsor, Eisai Limited, at: 1-877-873-4724.

This leaflet was prepared by Eisai Limited, Mississauga, ON L4W 5A4.

Last revised: January 17, 2013

HALAVEN® is a trademark owned by Eisai R&D Management Co., Ltd.